血管內皮生長因子B(VEGFB)多克隆抗體
Polyclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB)
VEGF-B; VEGFL; VRF; VEGF-Related Factor
- 編號PAA144Bo01
- 物種Bos taurus; Bovine (Cattle，牛) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPA144Bo01-血管內皮生長因子B(VEGFB)重組蛋白
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度500μg/mL
- 且適物種Homo sapiens (Human，人), Mus musculus (Mouse，小鼠), Rattus norvegicus (Rat，大鼠)
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 680 ¥ 1588 ¥ 2268 ¥ 5670 ¥ 22680
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
Figure. Western Blot; Sample: Recombinant VEGFB, Bovine.
-
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對VEGFB的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別VEGFB。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩定性
熱穩定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
贈品
增值服務
相關產品
| 編號 | 適用物種：Bos taurus; Bovine (Cattle，牛) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA144Bo02 | 血管內皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA144Bo01 | 血管內皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA144Bo01 | 血管內皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA144Bo02 | 血管內皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
參考文獻
| 雜志 | 參考文獻 |
| International Journal of Cardiology | Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. [PubMed: 22459379] |
| Applied Sciences-Basel | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study [pubmed:29099033] |
| Journal of Endocrinological Investigation | Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell [10.1007/s40618-017-0677-z] |
| EXCLI Journal | Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction [] |
| Cancer Chemother Pharmacol | Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors [34164713] |
留言咨詢
